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Adrenomedullin (AM) is a newly discovered hypotensive peptide which is believed to play an important role for blood
pressure control in the adult. Although it has been well established that a major production site of AM is vascular
endothelial cells, we now show that AM is most highly expressed in trophoblast giant cells, which are derived from the
conceptus and are directly in contact with maternal tissues at the implantation site. Northern blot and in situ hybridization
analyses show that the AM mRNA begins to be detected just after implantation and its level peaks at 9.5 days
postconception (d.p.c.) in those cells. Expression then falls dramatically after 10.5 d.p.c., coincident with the completion of
the mature chorioallantoic placenta. Immunohistochemical analyses show that the AM peptide is secreted from the
trophoblast giant cells into the surrounding tissues, i.e., embryo, decidua, and maternal circulation. In contrast, the
expression of an AM receptor was not detected by Northern blot analyses in either embryo or trophoblast giant cells at
7 d.p.c., when the AM gene is most highly expressed in the trophoblast giant cells. This suggests that the AM produced and
secreted from the embryo’s trophoblast giant cells acts on the maternal tissues rather than on the embryonic tissues. Based
on these results, we propose that the high production of AM may be the mechanism by which the embryos survive at the
early postimplantation period by pooling maternal blood in the implantation site in order to secure nutrition and oxygen
before the establishment of efficient embryo-maternal circulation through the mature placenta. © 1998 Academic Press
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INTRODUCTION
The rapidly growing mammalian embryo must interface
with its mother for nourishment and respiration. The
failure to establish this critical contact results in the loss of
the embryo in utero (Copp, 1995; Cross et al., 1994). For
survival through the peri-implantation stage, one of the key
players is the trophoblast giant cell. These cells are derived
from the conceptus and are directly in contact with mater-
nal tissues at the implantation site (Hoffman and Wooding,
1993; Rossant, 1986). To understand the functions of tro-
phoblast cells as well as other cells at the implantation site,
we are constructing a catalog of genes expressed in those
cells by sequencing randomly chosen cDNA clones made
from the ectoplacental cone (EPC) of 7.5 days postconcep-
tion (d.p.c.) mouse embryos. While working on this se-
quencing project, we encountered cDNA clones which were
clearly identified as the mouse adrenomedullin (AM) gene.
AM is a hypotensive peptide that reduces blood pressure
without changing the heart rate (Kitamura et al., 1993a,b;
Richards et al., 1996; Sakata et al., 1993). The human AM
peptide, consisting of 52 amino acids, was originally iso-
lated from an adrenal pheochromocytoma (Kitamura et al.,
1993a). The AM peptide is processed from a precursor
which is 185 amino acids in length and shows a slight
homology to the calcitonin gene related peptide (CGRP).
The AM gene is expressed in a wide variety of tissues, such
as the adrenal gland, lung, kidney, and heart (Ichiki et al.,
1994; Kitamura et al., 1993b; Sakata et al., 1993, 1994). The
highest expression of the gene has been observed in vascular
endothelial cells, which secrete the peptide (Sugo et al.,
1994); this has suggested paracrine and/or autocrine control
of blood pressure by AM (Ishizaka et al., 1994; Richards et
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al., 1996). In fact, concentrations of the AM peptide in
human plasma are elevated in patients with essential hy-
pertension, congestive heart failure, and renal failure (Ish-
imitsu et al., 1994b; Jougasaki et al., 1995b). Also, the level
of AM mRNA is significantly induced in ischemic brain
cortex (Wang et al., 1995). These findings suggest that AM
plays important physiological and pathophysiological roles
in cardiovascular systems.
It has been reported recently that the AM peptide plays
more diversified roles such as natriuretic (Jougasaki et al.,
1995a) and bronchodilatory functions (Kanazawa et al.,
1994) and regulation of insulin (Martinez et al., 1996) and
pituitary adrenocorticotropin secretion (Samson et al.,
1995). In addition, the involvement of AM in the regulation
of cellular growth (Withers et al., 1996) and elevated expres-
sion of the AM gene in tumor cell lines (Miller et al., 1996)
have been reported.
We were intrigued by the unexpected expression of the
AM gene at the peri-implantation stage and decided to
examine this in more detail. Here we report the cloning,
sequencing, genetic mapping, and expression analyses of
the mouse AM and its receptor genes. We show expression
of the mouse AM gene in the trophoblast giant cells during
the peri-implantation period by in situ hybridization, and
we discuss the new role of trophoblast giant cells in
controlling blood flow at the implantation site.
MATERIALS AND METHODS
Cloning and sequencing. Construction of the cDNA library
and the associated large-scale cDNA sequencing project will be
described elsewhere. The longest cDNA clone (C0010H07) was
selected for this analysis from the eight cDNA clones showing
strong similarity to the human AM gene. Cycle sequencing reac-
tions were carried out using Taq DyeDeoxy terminators (Applied
Biosystems), and the samples were run on a Model 377 DNA
sequencer (Applied Biosystems). A total 1381-bp cDNA sequence
was obtained and deposited to the GenBank public sequence
database (Accession No. U77630). The sequence revealed (GT)20
repeats in the 39-UTR. To exclude this repeat sequence for South-
ern, Northern, and in situ hybridization analyses, a 684-bp DNA
fragment was amplified by a PCR primer pair (AM5-1, 59-
CGCTGATGAGACGACAGTTC-39 ; AM3-1, 59-CATTG-
CACGTTCCTCGCTAGG-39), cloned into pCR-ScriptSK(1) (Strat-
agene), and named H0201A08. Sequence similarity searches were
performed by the BLAST program against the nonredundant se-
quence database in the NCBI (NIH) (Altschul et al., 1990). The
amino acid sequence was deduced from the nucleotide sequence
and analyzed by Genetyx-Mac 7.3 program (Software Development
Co.).
Whole-mount and section in situ hybridization. Both sense
and antisense single-stranded cRNA probes were synthesized from
the linearized plasmid (clone H0201A08) in the presence of
digoxigenin–UTP (Boehringer-Mannheim). Whole-mount in situ
hybridization was performed according to a published protocol
(Wilkinson, 1992). In situ hybridization of tissue sections was
carried out as described (Yotsumoto et al., 1996) with some
modifications, i.e., hybridization and washing were done at 68°C.
Immunohistochemistry. Immunohistochemical staining was
done as described. Briefly, sections were incubated with rabbit
anti-rat AM 1-50 serum (Peninsula Laboratories, Inc.) at 4°C
overnight. The serum was diluted 1:800 in PBS before use. Bound
polyclonal antibody was detected using the LSAB kit (DAKO Corp.)
using aminoethylcarbazole as a peroxidase substrate (red color in
the photographs). Control staining with either PBS or nonimmune
rabbit serum (DAKO Corp.) did not show any signals. To clearly
identify the trophoblast giant cells at the implantation site, some of
the serial sections were stained with rabbit anti-human keratin
serum (DAKO Corp.) according to the manufacturer’s instructions.
The sections were counterstained with Meyer’s hematoxylin.
Immunoblot analysis. The fresh embryo and placenta obtained
from a 12.5-day p.c. mouse were immediately minced and homog-
enized in RIPA buffer (PBS containing 1% NP-40, 0.5% sodium
deoxycholate, 0.1% SDS, 0.1 mg/ml of PMSF, and 0.27 TIU/ml of
aprotinin) in a conical glass homogenizer and centrifuged at 13,000
rpm for 15 min at 4°C. The supernatant fractions were subjected to
SDS–PAGE with a 17.5% gel, transferred to Immobilon (Millipore),
and allowed to react with rabbit anti-rat AM 1-50 serum (Peninsula
Laboratories, Inc.) diluted at 1:800 for overnight at 4°C. As a
negative control for the first antibody we used a normal rabbit IgG
(Sigma) diluted at 1:800. The secondary antibody was a peroxidase-
linked donkey anti-rabbit IgG (Amersham) diluted at 1:1000, which
was detected by H2O2 and diaminobenzidine.
Northern blot analysis. Total RNAs were isolated from de-
cidua and extraembryonic tissue with the embryo proper at 6.5 and
7.5 d.p.c.; decidua and extraembryonic tissue without the embryo
proper at 8.5, 9.5, and 10.5 d.p.c.; yolk sac and placenta at 12.5, 14.5,
16.5, and 18.5 d.p.c.; and adult adrenal glands and lungs by Micro
RNA Isolation kit (Stratagene). Poly(A)1 RNA for Northern analy-
sis was isolated from the total RNAs with an Oligotex mRNA Midi
kit (Qiagen). Four micrograms of poly(A)1 RNA [2 mg of poly(A)1
RNA for lung] was electrophoresed on a 1.2% agarose gel contain-
ing 6.3% formaldehyde. RNAs were transferred to Hybond N1
membrane (Amersham) using 203 SSC and the membrane was
hybridized for 1 h with an ExpressHyb hybridization solution
(Clontech) first to AM, then rehybridized to proliferin (PLF; clone
C0002G11), and finally rehybridized to b-actin (Clontech) probes.
The filter was washed with solution 1 (23 SSC, 0.05% SDS) at
room temperature for 40 min and then washed with solution 2
(0.13 SSC, 0.1% SDS) at 65°C for 40 min. The filter was then
exposed to phosphor screens to allow subsequent quantification
and then to autoradiographic film (Kodak X-OMAT AR). The
phosphor screens were scanned on a Storm 860 (Molecular Dynam-
ics) and individual bands were quantified using ImageQuant soft-
ware. After each hybridization, filters were washed in boiled 0.5%
SDS solution for 10 min to remove the labeled probe. Membranes
for staged mouse embryos and adult organs were purchased from
Clontech. Hybridization was performed according to the manufac-
turer’s instructions.
Mapping. Gene mapping by polymerase chain reaction (PCR)
was performed as described (Ko et al., 1994). For AM gene mapping,
the PCR primer pair used for genotyping was AM-up2, 59-
CGTGAATGTCTCAGCAAGGTG-39; and AM-dn1, 59-CGA-
TAATCAGGCGCTCTCCAC-39. The length of polymorphism
which distinguishes the PCR product (102 bp) of the C57BL/6J
allele from that (106 bp) of the Mus spretus allele was used to type
The Jackson Laboratory BSS Backcross DNA Panel [(C57BL/6JEi 3
SPRET/Ei) F1 3 SPRET/Ei] (Rowe et al., 1994). The polymorphism
was due to the (GT)n repeats in the 39-UTR of the AM cDNA.
For AM-R gene mapping, a primer pair for PCR was designed
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from the 39-end of the mouse expressed sequence tag (EST)
(W75568). Primer sequences are AMR-up2, 59-TCCATGCTG-
C A C T G T G T G G C - 3 9 ; a n d A M R - d n 1 , 5 9 - C G A T T C -
CCAACCCCACACGC-39. The annealing temperature for PCR
was 68°C and the size of the PCR product is 526 bp. The PCR
products amplified from the genomic DNAs of C57BL/6J and M.
spretus, respectively, were sequenced by an ABI 377 DNA se-
quencer. The sequence of the PCR product from M. spretus
genomic DNAs was deposited in GenBank (Accession No.
AF001229). The sequence comparison revealed a restriction frag-
ment length polymorphism (RFLP) at an AvaII site; the C57BL/6J
allele produced two fragments (81 and 445 bp) and the M. spretus
allele produced one 526-bp fragment. The RFLP was used to type
The Jackson Laboratory BSS Backcross DNA Panel [(C57BL/6JEi 3
SPRET/Ei) F1 3 SPRET/Ei] (Rowe et al., 1994).
The raw mapping data for the cross are accessible through The
Jackson Laboratory World Wide Web server [http://www.jax.org/
resources/documents/cmdata] and the Mouse Genome Database
(Accession Nos. MGD-JNUM-40224 and MGD-JNUM-38173).
RESULTS
cDNA cloning and sequence analysis of mouse AM.
While working on a single-pass sequencing project on our
cDNA library made from the ectoplacental cone (EPC) of
7.5 d.p.c. mouse embryos, we found 8 cDNA clones with
strong sequence similarity to human AM (Kitamura et al.,
1993b) of 2103 cDNA clones sequenced. Because the fre-
quency of the cDNA clones in the library roughly corre-
sponds to the expression levels of the genes in this tissue,
these data suggest that the mouse homolog of AM is highly
expressed in the EPC. Complete analysis of the cDNA
showed that its sequence agreed with an independently
determined mouse strain 129/SvJ AM cDNA sequence that
was reported while this paper was being prepared (Okazaki
et al., 1996). One amino acid of 184 was different, but
Southern blot analysis indicates that the gene is single copy
(data not shown), and the difference is most likely explained
by a sequence polymorphism between C57BL/6J mice,
which we employed, and 129/SvJ.
Expression analyses of mouse AM by Northern blot.
The high levels of AM mRNA at the implantation site
prompted us to investigate further the temporal, level, and
spatial distribution of its expression as indices of its pos-
sible involvement in the implantation phase. To our sur-
prise, Northern blot analysis of staged embryos from 7, 11,
15, and 17 d.p.c. mice showed that AM is most highly
expressed in the 7 d.p.c. mouse embryo (Fig. 1a). Then, the
expression level of AM became undetectably low at
11 d.p.c. The low level of AM gene expression was detected
at 15 d.p.c. and its expression was slightly increased by
17 d.p.c. In controls with adult mouse RNA preparations,
Northern analyses showed high expression of AM in heart,
lung, and kidney and weak expression in liver and skeletal
muscle (Fig. 1b). This pattern of tissue-specific expression
confirms results reported for rat (Sakata et al., 1993; Sugo et
al., 1994), porcine (Kitamura et al., 1994), and human
(Kitamura et al., 1993b) AM. In addition to a single major
transcript of about 1.5 kb, we observed a few minor tran-
scripts, which were also noted in rat (Sakata et al., 1993;
Sugo et al., 1994) and human studies (Kitamura et al.,
1993b).
Expression analyses of mouse AM by in situ hybridiza-
tion. Because the RNA preparation from the 7 d.p.c.
embryo contains both extraembryonic and embryonic tis-
sues and those from 11, 15, and 17 d.p.c. embryos contain
only the embryonic tissues, it is possible that this high
expression of the AM gene at 7 d.p.c. was contributed by the
expression of this gene in the extraembryonic tissues. To
localize better the site of expression, a digoxigenin-labeled
cRNA probe was hybridized to whole and sectioned em-
bryos from the implantation period of development. In
controls for all experiments, a sense probe invariably
showed no signal, as expected (e.g., Figs. 2b and 2d). In
contrast, an antisense probe showed very high expression of
the AM gene in relatively large cells on most of the embryo
surface at 7.5 and 8.5 d.p.c. (Figs. 2a and 2c).
More detailed analyses were done on sections of mouse
embryos from various stages. Expression of the AM gene
was first seen, though weakly, at 6.5 d.p.c. (Fig. 3a). At this
stage the expression was mainly localized to cells at the
border between maternal and fetal tissues, especially in the
antimesometrial region and the EPC (Fig. 3a). At 7.5 d.p.c.,
very strong and distinctive signals were observed in a ring of
FIG. 1. Stage-specific and tissue-specific expression of the AM
gene by Northern blot analyses. (a) A membrane (Clontech) con-
taining 2 mg of poly(A)1 RNA from 7, 11, 15, and 17 d.p.c. embryo
was hybridized with a 32P-labeled AM cDNA probe (clone
H0201A08) (top) and with a b-actin probe (bottom). The RNA
preparation from the 7 d.p.c. embryo contains extraembryonic
tissues, while those from embryos at other stages do not. (b) A
membrane (Clontech) containing 2 mg of poly(A)1 RNA from
various adult organs was hybridized with a 32P-labeled AM cDNA
probe (clone H0201A08) (top) and with a b-actin probe (bottom).
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cells lying at the interface between maternal and fetal
tissues (Fig. 3b). Histologic features and location identify
those cells unequivocally as trophoblast giant cells and
trophoblast cells in the EPC (Copp, 1995; Cross et al., 1994;
Hoffman and Wooding, 1993; Rossant, 1986). Identification
of the trophoblast giant cells was also confirmed by staining
the sections with rabbit anti-human keratin serum, which
is a well-known sensitive marker for the trophoblast cells
(Daya and Sabet, 1991) (data not shown). At 8.5 d.p.c., a
strong signal was still observed in the trophoblast giant
cells, but had declined sharply in the EPC (Figs. 2c and 3c).
Furthermore, the trophoblast giant cells at the antimesome-
trial region showed stronger signals than those at the
mesometrial region (Fig. 3c); the same cells account for
most of the observed expression at 9.5 d.p.c. (Figs. 3d–3f). At
12.5 d.p.c., weak expression of the AM gene was detected in
the limited number of trophoblast giant cells in the pla-
centa and yolk sac by in situ hybridization (data not shown).
Expression of the mouse AM gene in extraembryonic
tissues. Because expression of the AM gene is limited to
extraembryonic cells during early postimplantation devel-
opment, the expression of the gene in the trophoblast giant
cells could be quantitated further by Northern blot analyses
using poly(A)1 RNA extracted from the decidua and ex-
traembryonic parts of the staged mouse embryos. AM
expression was again first observed at about 6.5 d.p.c. and
then increased to a peak level at 9.5 d.p.c. (Fig. 4). Thereaf-
ter, by 12.5 d.p.c., expression dropped precipitously. Con-
sistent with the results by in situ hybridization, a low level
of AM gene expression was detected by Northern blot
analyses throughout the postimplantation period (Fig. 4). In
contrast, the expression of proliferin, an angiogenic placen-
tal hormone (Jackson et al., 1994) primarily expressed in the
trophoblast giant cells (Lee et al., 1988), started at about
8.5 d.p.c., peaked at 10.5 d.p.c., and was then continuously
expressed at a relatively high level until the end of gestation
(Fig. 4).
Expression of AM peptide examined by immunohisto-
chemistry. It has been known that, as with other biologi-
cally active peptides affecting circulation such as endothe-
lin and atrial natriuretic peptide, AM in the adult heart,
lung, and kidney is continuously secreted without storage
in the cytoplasm of synthesizing cells (Washimine et al.,
1995). To test the possibility of AM peptide secretion from
trophoblast giant cells, the distribution of AM peptide was
directly observed by immunohistochemistry with a rabbit
anti-rat AM 1-50 serum.
At 6.5 d.p.c., a weak signal was observed in the EPC and
surrounding maternal decidua in the mesometrial region
and in the yolk cavity in the antimesometrial region (Fig.
5a). Consistent with a paracrine and/or autocrine role, the
AM peptide was localized not only in the trophoblast giant
cells, along with its mRNA, but also in the decidua, embryo
proper, ectoplacental cavity, exocoelemic cavity, and yolk
sac cavity at 7.5 d.p.c. (Fig. 5b). At 8.5 d.p.c., strong signals
were observed particularly in the embryo proper, extraem-
bryonic tissues, and surrounding decidua at the antime-
sometrial region (Fig. 5c). In a magnified view of the yolk
sac area, a strong signal was observed in the yolk sac cavity
with a weaker signal in the trophoblast giant cells (Figs. 5d
and 5e). Interestingly, the AM peptide was concentrated in
the yolk cavity, where maternal blood cells and nascent
embryonic blood cells were very close to each other (Figs.
5d and 5e). In the mature placenta at 12.5 d.p.c., a weak
signal was observed in the mesometrial side of the spongio-
trophoblast layer and the trophoblast giant cells, but the
decidual region, especially loose decidua, was much more
intensely stained (Fig. 5f). In the magnified view it was clear
that the AM peptide was localized in the subregion of the
placenta, which was lined with trophoblast giant cells (Fig.
5g). Thus, the AM peptide consistently diffused primarily
outside of the trophoblast giant cells where it was produced.
This is in contrast to other secretory proteins such as
proliferin, whose both protein product and mRNA are
present at high levels in the trophoblast giant cells (Lee et
al., 1988).
To confirm that the rabbit anti-rat AM 1-50 serum used
in this study recognizes mouse AM in these particular
tissue sections, immunoblots of 12.5 d.p.c. embryo and
placenta extracts were performed (Fig. 6). Two proteins
with approximately 14.5- and 7.3-kDa molecular weights,
which correspond to those of pro-AM and AM, respectively,
were clearly detected in the placenta extract (Fig. 6, lane a).
The results were consistent with those reported previously
(Miller et al., 1996; Montuenga et al., 1997). Similar immu-
noreactive proteins were also detected in the embryo ex-
FIG. 2. Localization of mouse AM in the mouse embryo by whole-mount in situ hybridization. (a, b) Whole-mount in situ hybridization
of an embryo in utero at 7.5 d.p.c. by antisense probe (a) and sense probe (b). The decidua were cut to expose embryos. (c, d) Whole-mount
in situ hybridization of an embryo in utero at 8.5 d.p.c. by antisense probe (c) and sense probe (d). The embryo was cut out from the
deciduum. epc, ectoplacental cone; dec, decidua; tgc, trophoblast giant cell. Scale bar: 500 mm, all panels.
FIG. 3. Localization of mouse AM in the mouse embryo by in situ hybridization. (a) In situ hybridization of a section of embryo in utero
at 6.5 d.p.c. To enhance the signal intensity, a color expression time of this sample was extended to approximately threefold longer than
those of other stages. (b) In situ hybridization of a section of embryo in utero at 7.5 d.p.c. (c) In situ hybridization of a section of embryo
in utero at 8.5 d.p.c. (d, e) A pair of serial sections of embryos in utero at 9.5 d.p.c. One section is hybridized with antisense probe (d). The
other section is stained with hematoxylin and eosin (e). (f) Magnified view of antimesometrial region. MM, mesometrial; AMM,
antimesometrial; dec, decidua; e, embryo; epc, ectoplacental cone; tgc, trophoblast giant cells. Scale bars: 500 mm in a, 1 mm in b–e, and
100 mm in f.
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tract, although they were very faint (Fig. 6, lane b). The
controls using normal rabbit IgG did not detect any immu-
noreactive protein (Fig. 6, lanes c and d).
Identification of mouse AM-R cDNA. To investigate
the target tissues of the AM peptide secreted from the
trophoblast giant cells, we performed expression analyses of
the adrenomedullin receptor (AM-R) gene. AM-R was origi-
nally isolated as an orphan receptor from rat lung [L09249
(Harrison et al., 1993), L04672 (Eva and Sprengel, 1993)].
The cDNA encodes a protein that contains seven trans-
membrane domains and is a member of the G protein-
linked receptor superfamily. Later, Clark and associates
identified the cDNA clone for the AM-R based on two
criteria (Kapas et al., 1995). First, the expression pattern of
the gene is consistent with that of the AM gene. Both genes
are expressed predominantly in the lung, adrenal gland,
heart, and spleen. Second, they have demonstrated that
when the full-length cDNA is expressed in COS-7 cultured
cells, the receptor binds to adrenomedullin and mediates a
cAMP response in a manner similar to that observed in
cardiovascular and other target tissues.
By searching the public database (NCBI, NIH) with this
rat gene sequence, we found two mouse sequences showing
strong similarity to the rat AM-R gene. One mouse cDNA
sequence (D17292 [BALB/c]) was originally identified as a
putative G protein-coupled receptor with unknown func-
tion and deposited in the database (Saeki et al., 1993). The
other clone was an EST from the HHMI-Washington Uni-
versity Mouse EST Project (W75568 [C57BL/6J]; (Marra et
al., 1998)).
To determine whether the mouse gene (D17292) is the
ortholog of the rat AM-R gene, we have performed a
detailed sequence comparison between these genes. The
comparison was made by the Higgins–Sharp method (Hig-
gins and Sharp, 1988) using MacDNASIS sequence analyses
programs (Hitachi). The results shown in Fig. 7 clearly
demonstrate the high degree of sequence similarity be-
tween these genes and establish the mouse gene (D17292,
W75568) as the ortholog of the rat AM-R gene. The EST
clone (W75568) was purchased from Research Genetics and
resequenced to confirm the identity. Although there are
some sequence variations between the EST (W75568) and
the cDNA (D17292), this is probably due to the slight
sequence difference between the mouse strain C57BL/6J
and BALB/c. The uniqueness of the EST clone was con-
firmed by Southern blot analysis (data not shown).
Expression analyses of AM-R by Northern blot. North-
ern blot analysis using the mouse EST cDNA clone
(W75568) as a probe showed one major band at about 1.8 kb
and some minor bands at about 2.2, 3.0, and 4.4 kb. The
gene was highly expressed in lung, liver, heart, spleen, and
kidney (Fig. 8a). The size of transcripts and tissue-specific
expression pattern are similar to those reported for rat
AM-R (Kapas et al., 1995). The tissues expressing the AM-R
gene corresponded well to those expressing the AM gene
(Figs. 1b and 8a). The results were consistent with a
paracrine mechanism for the action of AM peptide.
To our surprise, the expression pattern of the AM-R gene
during early mouse development showed a sharp contrast
with that of the AM gene (Figs. 1a and 8b). The expression
level of the AM-R gene was undetectably low at 7 and
11 d.p.c., but dramatically increased by 15 d.p.c. and stayed
relatively high until 17 d.p.c. Further analyses of AM-R
gene expression in the extraembryonic tissues using the
same membrane as used in Fig. 4 also showed very low
expression throughout the postimplantation period (data
not shown). These data indicate that the AM-R gene is not
expressed in either embryonic or extraembryonic tissues at
7.5 d.p.c., while the AM gene is highly expressed in the
extraembryonic tissues, especially in the trophoblast giant
cells at this stage. This suggests an intriguing possibility
that the maternal tissues, especially maternal decidua
and/or mother’s body, are the target of the AM peptide that
is synthesized and secreted from the embryo’s trophoblast
giant cells at the implantation site. Histological observa-
tions (e.g., Figs. 5d and 5e) showed that the trophoblast
giant cells are in direct contact with maternal blood,
suggesting the possibility that the AM peptide is also
secreted into the maternal circulation.
Genetic mapping of mouse AM and AM-R on the mouse
genome. Since the primary function of the AM peptide is
the control of blood pressure, it is now reasonable to
suspect that AM is a candidate gene in the causation of
preeclampsia, the gestational proteinuric hypertension
(Sibai, 1996) that is believed to be caused by insufficient
invasion of trophoblasts into the uterine stroma (Cross et
al., 1994; Wegner and Carson, 1994). To examine this
possibility, we have mapped both AM and AM-R on the
mouse genetic map by using The Jackson Laboratory’s
Interspecific Backcross Mouse Panel (Rowe et al., 1994).
Analysis of the genotype using the MapManager Program
(Manly, 1993) has mapped the mouse AM gene (locus
FIG. 5. Immunohistochemical analysis by affinity-purified antibody raised against rat AM. (a) Embryo in utero at 6.5 d.p.c. (b) Embryo in utero
at 7.5 d.p.c. (c) Embryo and deciduum in the antimesometrial side at 8.5 d.p.c. (d, e) Magnified view of boundary between the trophoblast giant
cells and maternal deciduum at 8.5 d.p.c. in the antimesometrial side. (f) Placenta at 12.5 d.p.c. (g) Magnified view of a part of placenta. MM,
mesometrial; AMM, antimesometrial; dec, decidua; ec, ectoplacental cavity; exc, exocoelemic cavity; amc, amniotic cavity; rm, Reichert’s
membrane; yc, yolk cavity; mbc, maternal blood cells; pe, parietal endoderm; ve, visceral endoderm; ebc, embryo blood cells; mu, muscle layer
of uterus; e, embryo; epc, ectoplacental cone; la, labyrinthine trophoblast; sp, spongiotrophoblast; tgc, trophoblast giant cells; lde, loose decidua;
cde, compact decidua. Scale bars: 200 mm in a–c, 50 mm in d and e, 1 mm in f, and 100 mm in g.
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symbol Adm) on chromosome 7: two crossovers of 94
backcross animals distal to D7Mit37 and the Hbb locus;
and the mouse AM-R gene (locus symbol Admr) to the
distal end of mouse chromosome 10, D10Mit35-(1.06 6
1.06)-D10Wsu93e-(1.06 6 1.06)-Dagk1-(1.06 6 1.06)-Admr,
Atoh3, Cd63-(1.06 6 1.06)-Apof. The hormone and its
receptor were not linked on the mouse genome in this case.
The region where the AM gene (Adm) was mapped is
syntenic with human chromosome 11p15.5, where the
human AM is already mapped (Brilliant et al., 1996; Ishim-
itsu et al., 1994a; Okazaki et al., 1996). The human ortholog
of the AM-R gene may map to 12q13 based on the syntenic
correlation between this region of the mouse genome and
human chromosome 12q13.3. Because the linkage studies
have limited the location of the preeclampsia gene in
humans to chromosome 1, 3, 9, or 18 (Hayward et al., 1992),
this makes it unlikely that both AM and AM-R are candi-
date genes for preeclampsia. We also could not find any
known loci with phenotypes that affect blood pressure by
searching the Online Mendelian Inheritance of Man
(OMIM).
DISCUSSION
In this report, we have shown that mouse AM is most
highly expressed in the early postimplantation stage by
Northern blot analyses. It is unlikely that the AM gene is
expressed at the stages before implantation, because a
large-scale cDNA sequencing analysis of 3.5 d.p.c. mouse
blastocysts, which are at a stage immediately before im-
plantation, did not show any hits to the AM gene in the
collection of more than 6000 ESTs (M.S.H.K., unpublished
observation). Therefore, we can conclude that the AM gene
shows a spike-like expression pattern with peaks at 7–9
d.p.c. during mouse development, although a relatively
lower level of expression was detected throughout the
postimplantation period. Extensive examination of whole
mounts and sections observed by in situ hybridization
(6.5–9.5 d.p.c.) evidenced AM expression only in the tropho-
blast cells. Although at later stages such as 12.5 d.p.c. the
expression of the AM gene became evident in the embryo
proper, e.g., in the neuroepithelium (data not shown), these
expression levels were much less than those in the tropho-
blast giant cells at its peak expression. This indicates that
the peak production of AM mRNAs was exclusively from
the trophoblast giant cells at these stages.
It has been known that the vascular endothelial cells
show the highest expression level of AM gene in adult (Sugo
et al., 1994), suggesting that the tissue is a primary produc-
tion site of AM peptide. The expression of AM in mouse
trophoblast giant cells can be compared to that in cultured
rat vascular endothelial cells, which have been reported to
express AM at levels 20- to 40-fold higher than those of
adult lung and adrenal gland (Sugo et al., 1994). In the
mouse embryonic tissues used in our analyses the expres-
sion level of AM at 9.5 d.p.c. is 7- to 8-fold higher than that
of the adrenal gland and lung of the mature animal (Figs. 4a
and 4b). Because the trophoblast giant cells only occupy a
tiny fraction of the cells in the tissue mass used for RNA
FIG. 4. Expression of the AM gene in the extraembryonic tissues
during mouse development. (a) Four micrograms of poly(A)1 RNA
from each tissue except for lung (2 mg) was hybridized with a
32P-labeled cDNA probe from the AM (clone H0201A08) (first
panel), proliferin (PLF) (clone C0002G11) (third panel), and b-actin
(fourth panel). The second panel shows the result of the AM probe
after 6 days exposure with intensifying screen at 280°C. Poly(A)1
RNAs were purified from the following tissues at each develop-
mental stage: whole decidua including extraembryonic tissue and
embryo proper (6.5 and 7.5 d.p.c.); decidua and extraembryonic
tissue, but without embryo proper (8.5, 9.5, and 10.5 d.p.c.); yolk
sac and placenta (12.5, 14.5, 16.5, and 18.5 d.p.c.); adult adrenal
glands and lungs. (b) Relative changes in mRNA level of AM (black
bars) and PLF (white bars; normalized against b-actin) are shown as
percentage of maximum.
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extraction (Figs. 2 and 3), one can estimate that the expres-
sion of AM in trophoblast giant cells reaches levels at least
an order of magnitude higher than in cultured vascular
endothelial cells. One can therefore infer that AM is ex-
pressed most in the trophoblast giant cells during embryo-
genesis and consequently may have a primary function
soon after implantation.
While preparing this paper, a developmental study of the
expression patterns of AM and AM-R in rat and mouse was
published (Montuenga et al., 1997). Although the authors
emphasize mainly the role of AM in late postimplantation
development, they also point out that the AM gene is
expressed in trophoblast cells as well as many other cell
types at the implantation site. However, there are some
discrepancies between the current report and their report.
First, the authors reported that the AM gene is expressed
rather ubiquitously and expressed in both decidual cells and
trophoblast giant cells at 8–9 d.p.c. (Montuenga et al.,
1997), while we observed the expression of the AM gene
predominantly in the trophoblast giant cells at these stages.
Second, the authors reported that the AM-R gene is also
expressed at high levels in the trophoblast giant cells at 8–9
d.p.c. (Montuenga et al., 1997), while we could not detect
the expression of the AM-R gene in the trophoblast giant
cells by Northern blot analyses. Although we do not yet
know the reason for these discrepancies, the different
observations in the expression patterns of AM and AM-R at
the implantation site led two groups to different sugges-
tions about the role of the AM system at the implantation
site. In contrast to our ideas discussed in this paper,
Montuenga and associates suggest the involvement of the
AM system in the invasion of the trophoblast giant cells
into the maternal decidua by autocrine growth-promoting
mechanisms based on their observation that both AM and
AM-R genes are expressed in the trophoblast giant cells.
However, this idea does not seem to be consistent particu-
larly with one of our results, which shows that at 8.5 and
FIG. 6. Immunoblot analysis. The homogenates of 12.5 d.p.c.
mouse placenta and embryo were separated by SDS–PAGE, trans-
ferred to Immobilon membrane, and reacted with rabbit anti-rat
AM 1-50 serum (a and b) or normal rabbit IgG (c and d). Molecular
weight markers are indicated on the left. Lanes a and c represent
protein fractions of mouse placenta, and lanes b and d represent
protein fractions of mouse embryo. Arrows indicate immunoreac-
tive proteins.
FIG. 7. Sequence comparison of the adrenomedullin receptor
gene. Percentage similarities between cDNA sequences at the
nucleotide level are shown for the 59-UTR, protein coding region,
and 39-UTR, respectively. For protein coding regions, percentage
similarities between cDNA sequences in the amino acid level are
shown in parentheses. The locations of PCR primer pairs for gene
mapping are shown by arrows.
FIG. 8. Stage-specific and tissue-specific expression of the ad-
renomedullin receptor gene by Northern blot analysis. (a) A mem-
brane (Clontech) containing 2 mg of poly(A)1 RNA from 7, 11, 15,
and 17 d.p.c. embryo was hybridized with a 32P-labeled ad-
renomedullin receptor cDNA probe (W75568). The RNA prepara-
tion from 7 d.p.c. embryo contains extraembryonic tissues, while
those from embryos at other stages do not. (b) A membrane
(Clontech) containing 2 mg of poly(A)1 RNA from various adult
organs was hybridized with a 32P-labeled mouse adrenomedullin
cDNA probe (W75568).
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9.5 d.p.c. the expression of AM is mainly in the antime-
sometrial side and its expression in the mesometrial side is
very weak (Figs. 3c and 3d). If the AM is functioning for the
invasion of trophoblast and embryo into the maternal
decidua, we should have seen a stronger expression of AM
in the mesometrial side than in the antimesometrial side.
Indeed, such an expression pattern has been observed for
gelatinase B, which is directly involved in implantation and
the invasion of trophoblast cells into the maternal decidua
(Alexander et al., 1996).
The unique expression pattern of AM corresponds very
well with the dramatic changes in the support mechanism
for embryos during the peri-implantation stage (Copp, 1995;
Cross et al., 1994). Just after implantation (5.5–7.5 d.p.c.),
the embryo relies on surrounding maternal blood for life
support. Then, from 7.5 to 9.5 d.p.c., the rapidly developing
EPC and allantois—that is, the nascent precursor of the
chorioallantoic placenta—become the means for life sup-
port, especially on the mesometrial side of embryonic
tissues. For the rest of the embryo, especially in the antime-
sometrial side, the major route of transport for nutrients is
through the yolk sac. This is the exact period when AM
production sharply begins and peaks. Around 10 d.p.c.,
when the mature chorioallantoic placenta is completed,
there is a simultaneous sharp decline in AM production. At
this point the chorioallantoic placenta begins to provide
much more efficient nourishment through the umbilical
cord and into the embryonic circulation. Both Northern
blot and in situ hybridization analyses show high levels of
AM gene expression in trophoblast cells during the period
when the embryo relies on inefficient modes of obtaining
nourishment; the decline of AM production occurs as the
chorioallantoic placenta is established. Especially sugges-
tive are the in situ hybridization results showing high levels
of AM gene expression in the trophoblast giant cells of the
antimesometrial region at 8.5 and 9.5 d.p.c. (Figs. 3c, 3d, and
3f). Of course, residual AM may also function in the mature
placenta, where many vascular control mechanisms are
known (Myatt, 1992). For example, AM has recently been
detected in human cytotrophoblasts cultured from term
placenta (Morrish et al., 1996) and in human second-
trimester amniotic fluid as well as amniotic membrane
(Macri et al., 1996). It has also been reported that the serum
AM level of pregnant woman at 36–41 weeks gestation is
higher than that of nonpregnant woman (Di Iorio et al.,
1997).
The specific expression of the AM gene in the trophoblast
giant cells coincides with the known critical function of the
cells, which act (i) as the leading edge of embryo invasion of
the maternal endometrium; (ii) as an immunological barrier
protecting the embryo from the maternal immune re-
sponse; and (iii) as an endocrine organ, synthesizing and
secreting steroid and peptide hormones (Cross et al., 1994;
Hoffman and Wooding, 1993; Rossant, 1986). The results
presented in this report suggest that AM secretion is a
significant feature of the endocrine function of trophoblast
giant cells. This new feature highlights a similarity of the
trophoblast giant cells to vascular endothelial cells. A
speculative similarity has been suggested earlier, based on
the anatomical juxtaposition of both cell types in direct
contact with blood (Cross et al., 1994), although the em-
bryological origins of the two cell types are completely
different (Risau, 1995; Rossant, 1986). In this sense, our
results further support the recent report showing a striking
similarity between human cytotrophoblast cells and vascu-
lar endothelial cells by examining the cell adhesion pheno-
type switch (Zhou et al., 1997).
Concerning AM function as a hypotensive peptide, in
adult animals the targets of AM are believed to be both
vascular smooth muscle cells and endothelial cells in the
aorta (Shimekake et al., 1995). Because there are no vascular
smooth muscle cells underlying the trophoblast giant cells,
the target of AM at the implantation site could be the
trophoblast giant cells themselves. However, the undetect-
able level of AM receptor gene expression in both embryo
proper and extraembryonic tissues including the tropho-
blast giant cells at the implantation site strongly suggests
that the AM peptide produced and secreted from the tro-
phoblast giant cells at the implantation site has a target in
the maternal tissues. According to the commonly accepted
paracrine/autocrine paradigm of the AM peptide function,
we propose that AM acts on the blood vessels in the
maternal decidua and enhances local circulation by pooling
maternal blood at the implantation site. Alternatively, AM
could influence maternal systemic blood pressure at the
very early postimplantation period.
Whatever the mode of AM action, its involvement in
embryonic metabolism and survival has implications for
maternal–fetal medicine. They range from possible side
effects of AM administered as an antihypertensive drug for
pregnant women to a potential therapeutic use to control
the implantation process. Obviously, the production of an
AM knock-out mouse will provide a useful model to test
these ideas.
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